Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $59.15 USD
Change Today -0.96 / -1.60%
Volume 131.6K
IART On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 4:30 PM 03/6/15 All times are local (Market data is delayed by at least 15 minutes).

integra lifesciences holding (IART) Snapshot

Open
$59.69
Previous Close
$60.11
Day High
$60.23
Day Low
$58.76
52 Week High
03/2/15 - $61.26
52 Week Low
04/11/14 - $42.50
Market Cap
1.9B
Average Volume 10 Days
257.1K
EPS TTM
$2.19
Shares Outstanding
32.8M
EX-Date
--
P/E TM
27.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for INTEGRA LIFESCIENCES HOLDING (IART)

Related News

No related news articles were found.

integra lifesciences holding (IART) Related Businessweek News

No Related Businessweek News Found

integra lifesciences holding (IART) Details

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in five segments: U.S. Neurosurgery; U.S. Extremities; U.S. Instruments; U.S. Spine and Other; and International. Its orthopedics products include specialty metal implants for surgery of the extremities, shoulder, and spine; orthobiologic products for repair and grafting of bone, including demineralized bone products, collagen ceramic matrices, and synthetic bone grafting solutions; dermal regeneration products and tissue-engineered wound dressings; and nerve and tendon repair products. The company also offers spinal fusion technologies comprising integrated interbody fusion devices, minimally invasive solutions, and deformity correction products; and neurosurgery and critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. In addition, it provides extremity products, including bone and joint fixation devices, implants and instruments for osteoarthritis, rheumatoid arthritis, wrist and shoulder arthroplasty, carpal tunnel syndrome, and cubital tunnel syndrome, as well as regenerative medicine devices for the treatment of acute and chronic wounds, peripheral nerve repair and protection and tendon repair, and bone graft substitutes. Further, the company offers instruments products, such as specialty and general surgical and dental instruments; and surgical lighting for hospitals, outpatient surgery centers, and physician, veterinarian, and dental practices. Integra LifeSciences Holdings Corporation sells its products directly through various sales forces and other distribution channels in the United States and internationally. The company was founded in 1989 and is headquartered in Plainsboro, New Jersey.

3,400 Employees
Last Reported Date: 02/27/15
Founded in 1989

integra lifesciences holding (IART) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $787.1K
President of Specialty Surgical Solutions and...
Total Annual Compensation: $335.1K
Corporate Vice President, General Counsel, Ad...
Total Annual Compensation: $355.7K
Compensation as of Fiscal Year 2013.

integra lifesciences holding (IART) Key Developments

IART Seeks Acquisitions

Integra LifeSciences Holdings Corporation (NasdaqGS:IART) is looking for acquisition opportunities. IART believe that given our ongoing strategy of seeking acquisitions, our continuing focus on rationalizing our existing manufacturing and distribution infrastructure and our continuing review of various product lines in relation to our current business strategy, some of the special charges discussed above could recur with similar materiality in the future.

Integra LifeSciences Holdings Corporation Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Reports Impairment Charges for the Fourth Quarter Ended December 31, 2014; Provides Earnings Guidance for the Year Ending December 31, 2015

Integra LifeSciences Holdings Corporation reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported total revenues of $252,176,000 against $220,769,000 a year ago. Operating income was $26,684,000 against $17,619,000 a year ago. Income before income taxes was $20,275,000 against $12,708,000 a year ago. Net income was $17,166,000 against $13,771,000 a year ago. Diluted net income per share was $0.52 against $0.45 a year ago. Adjusted EBITDA was $58,200,000 against $42,662,000 a year ago. Adjusted net income was $31,280,000 against $25,374,000 a year ago. Adjusted diluted net income per share was $0.94 against $0.83 a year ago. GAAP Net cash provided by operating activities was $20,759,000 against $11,696,000 a year ago. Purchases of property and equipment were $12,455,000 against $10,128,000 a year ago. For the year, the company reported total revenues of $928,305,000 against $836,214,000 a year ago. Operating income was $65,541,000 against operating loss of $10,156,000 a year ago. Income before income taxes was $42,979,000 against loss before income taxes of $31,302,000 a year ago. Net income was $34,004,000 against net loss of $21,067,000 a year ago. Diluted net income per share was $1.03 against $0.74 a year ago. Adjusted EBITDA was $188,015,000 against $132,436,000 a year ago. Adjusted net income was $97,605,000 against $66,472,000 a year ago. Adjusted diluted net income per share was $2.96 against $2.31 a year ago. GAAP Net cash provided by operating activities was $79,463,000 against $53,268,000 a year ago. Purchases of property and equipment were $41,921,000 against $47,851,000 a year ago. For the quarter, the company reported impairment charges of $190,000 against $340,000 a year ago. For the year ending December 31, 2015, the company expects GAAP net income to be in the range of $29,040,000 - $35,040,000, adjusted net income to be in the range of $102,200,000 - $108,200,000, GAAP diluted net income per share to be in the range of $0.87- $1.05 and adjusted diluted net income per share to be in the range of $3.05- $3.23. The company expects full year 2015 revenues to be between $960 million and $980 million. This guidance includes the performance of the spine business for the full year. At current foreign currency exchange rates, the company expects a negative impact of approximately $25 million on 2015 revenues, and a $0.10 to $0.15 negative impact on adjusted earnings per share, compared to what they would have been at 2014 average rates. In 2015, the company expects cash flow from operations to be in a range of $80 million to $90 million, with capital expenditures between $40 million and $45 million and free cash flow conversion of 36% to 45%. For 2015, the company expects GAAP gross margin in a range between 61.5% and 62%, the adjusted gross margin between 65.5% and 66%.

Integra LifeSciences Holdings Corporation Presents at Raymond James & Associates 36th Annual Institutional Investors Conference, Mar-02-2015 07:30 AM

Integra LifeSciences Holdings Corporation Presents at Raymond James & Associates 36th Annual Institutional Investors Conference, Mar-02-2015 07:30 AM. Venue: JW Marriott Grande Lakes, 4040 Central Florida Parkway, Orlando, FL 32837, United States. Speakers: Glenn G. Coleman, Chief Financial Officer, Principal Accounting Officer and Corporate Vice President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IART:US $59.15 USD -0.96

IART Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Chemed Corp $115.48 USD -1.22
Globus Medical Inc $23.64 USD -0.12
Masimo Corp $30.22 USD -0.90
NuVasive Inc $44.92 USD -0.31
Medicines Co/The $28.78 USD -0.86
View Industry Companies
 

Industry Analysis

IART

Industry Average

Valuation IART Industry Range
Price/Earnings 58.3x
Price/Sales 2.1x
Price/Book 2.8x
Price/Cash Flow 42.5x
TEV/Sales 1.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTEGRA LIFESCIENCES HOLDING, please visit www.integralife.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.